Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

被引：0

作者：

Nicholls, Stephen ^{[1
]}

Nelson, Adam ^{[1
]}

Ditmarsch, Marc ^{[2
]}

Kastelein, John ^{[2
]}

Ballantyne, Christie ^{[3
]}

Ray, Kausik ^{[4
]}

Navar, Ann Marie ^{[5
]}

Nissen, Steven ^{[6
]}

Goldberg, Anne ^{[7
]}

Brunham, Liam ^{[8
]}

Wuerdeman, Erin ^{[9
]}

Neild, Annie ^{[10
]}

Kling, Douglas ^{[11
]}

Hsieh, Andrew ^{[12
]}

Ference, Brian ^{[13
]}

Laufs, Ulrich ^{[14
]}

Banach, Maciej ^{[15
]}

Mehran, Roxana ^{[16
]}

Catapano, Alberico ^{[17
]}

Davidson, Michael ^{[2
]}

机构：

[1] Victorian Heart Hosp, Clayton, Vic, Australia

[2] New Amsterdam Pharma, Amsterdam, Netherlands

[3] Baylor Coll Med, Houston, TX 77030 USA

[4] Imperial Coll London, London, England

[5] UT Southwestern Med Ctr, Dallas, TX USA

[6] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ British C0lumbia, Vancouver, BC, Canada

[9] NewAmsterdam Pharma, Cincinnati, OH USA

[10] NewAmsterdam Pharma, Aventura, FL USA

[11] NewAmsterdam Pharma, Lebanon, NJ USA

[12] Univ Illinois, Long Grove, IL USA

[13] Deep Causal AI, Cambridge, England

[14] Univ Clin Leipzig, Leipzig, Germany

[15] Med Univ Lodz, Lodz, Poland

[16] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[17] Univ Milan, Milan, Italy

来源：

CIRCULATION | 2024年 / 150卷 / 25期

关键词：

CETP inhibitors; Lipids; Clinical trials; Dyslipidemia; Prevention;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4171281

引用

页码：E729 / E730

页数：2

共 50 条

[21] Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia - A randomized controlled trial
Stein, EA
Illingworth, DR
Kwiterovich, PO
Liacouras, CA
Siimes, MA
Jacobson, MS
Brewster, TG
Hopkins, P
Davidson, M
Graham, K
Arensman, F
Knopp, RH
DuJovne, C
Williams, CL
Isaacsohn, JL
Jacobsen, CA
Laskarzewski, PM
Ames, S
Gormley, GJ
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (02): : 137 - 144
[22] One-year efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia
Hedman, M
Matikainen, T
Föhr, A
Lappi, M
Piippo, S
Nuutinen, M
Antikainen, M
EUROPEAN HEART JOURNAL, 2004, 25 : 37 - 38
[23] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Ginsberg, Henry N.
Rader, Daniel J.
Raal, Frederick J.
Guyton, John R.
Baccara-Dinet, Marie T.
Lorenzato, Christelle
Pordy, Robert
Stroes, Erik
CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (05) : 473 - 483
[24] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Henry N. Ginsberg
Daniel J. Rader
Frederick J. Raal
John R. Guyton
Marie T. Baccara-Dinet
Christelle Lorenzato
Robert Pordy
Erik Stroes
Cardiovascular Drugs and Therapy, 2016, 30 : 473 - 483
[25] The Efficacy of Colesevelam HCl in the Treatment of Heterozygous Familial Hypercholesterolemia in Pediatric and Adult Patients
Davidson, Michael
CLINICAL THERAPEUTICS, 2013, 35 (08) : 1247 - 1252
[26] Efficacy of colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia(FH)
Kawashiri, MA
Higashikata, T
Nohara, A
Kobayashi, J
Inazu, A
Koizumi, J
Mabuchi, H
CIRCULATION JOURNAL, 2005, 69 (05) : 515 - 520
[27] Heterozygous familial hypercholesterolemia
Ozcan, Ozgr Ulas
Gulec, Sadi
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 10 - 18
[28] Heterozygous Familial Hypercholesterolemia
Onorato, Angela
Sturm, Amy C.
CIRCULATION, 2016, 133 (14) : E587 - E589
[29] Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Santos, Raul D.
Wiegman, Albert
Caprio, Sonia
Cariou, Bertrand
Averna, Maurizio
Poulouin, Yann
Scemama, Michel
Manvelian, Garen
Garon, Genevieve
Daniels, Stephen
JAMA PEDIATRICS, 2024, 178 (03) : 283 - 293
[30] Lipoprotein(a) metabolism in patients with heterozygous familial hypercholesterolemia
Parhofer, KG
Ritter, MM
Geiss, C
Schwandt, P
ATHEROSCLEROSIS, 1997, 134 (1-2) : 146 - 146

← 1 2 3 4 5 →